GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
THE SHORT REPORT- GNRC
WE opined on the idea of GNRC as a short when we we their ad for a solar set up.
All their generators run on Diesel so they are not being run. If you have a small house you are apt to just take the blackout now. Most cannot afford to constantly run their GNRC generator.
Generac named a short by Spruce Point, sees shares as 'materially overvalued' 08:47 GNRC
WE opined on the idea of GNRC as a short when we we their ad for a solar set up.
All their generators run on Diesel so they are not being run. If you have a small house you are apt to just take the blackout now. Most cannot afford to constantly run their GNRC generator.
Generac named a short by Spruce Point, sees shares as 'materially overvalued' 08:47 GNRC
Down 10%
THE CHILDREN STONEY!!!!!
THEY NEED SAFE STOCKS.
CSX----.> $28
WE HAVEN'T BOUGHT YET! VAN WHEN SOMETHING GOES BUY RATED AT GBA WE FOLLOW AND CHART FOR about TWO WEEKS-- THIS HAS ALWAYS BEEN THE WAY YOU ARE SO USED TO BUYING THE MOMENT WE UPGRADE- LET THINGS SETTLE- A LOT OF EYES ARE WATCHING US..
Buy DBX when we give the GO TIME! (maybe today!)
Stoney, you said "BUY DROPBOX", it was $23
But whatever.
Look at this chart.
This thing has $18 written all over it.
THE TIDE STONEY! THE TIDE!!!!
HEAD AND SHOULDERS BREACH SENDS IT TO $16
Northland 'confidently reiterating' Agilysys as top pick after meetings » 09:01 AGYS
5/18 <-- 1 month ago.
Agilysys price target raised to $50 from $45 at Craig-Hallum 05/18 AGYS, ORCL Craig-Hallum analyst George Sutton raised the firm's price target on Agilysys (AGYS) to $50 from $45 and keeps a Buy rating on the shares following quarterly results. Following a few years of heavy R&D investment, the company is clearly demonstrating that it has outmaneuvered its largest competitor in hospitality software, Oracle (ORCL), who barely addresses the business unit on its earnings calls, the analyst notes. Sutton also likes the company's position against its macro-environment, where five out of the seven key verticals are still in recovery, providing incremental upside potential.
GBA UPGRADE TO BUY- AGYS $39.50
Roth says timing of FDA nicotine decision 'couldn't be better' for 22nd Century 08:34 XXII Roth Capital analyst Brian Wright notes the FDA officially announced it will be pursuing a maximum nicotine content level in all cigarettes sold in the United States. While this is an early step in a multi-year process with the proposed rule not expected until May 2023, the timing of the decision couldn't be better for 22nd Century's launch of its 95% reduced nicotine content cigarettes, the analyst contends. These are the only FDA-approved minimum nicotine content cigarettes on the market, he adds. Wright reiterates a Buy rating on 22nd Century's shares with a price target of $6.
5/18 <-- 1 month ago.
Agilysys price target raised to $50 from $45 at Craig-Hallum 05/18 AGYS, ORCL Craig-Hallum analyst George Sutton raised the firm's price target on Agilysys (AGYS) to $50 from $45 and keeps a Buy rating on the shares following quarterly results. Following a few years of heavy R&D investment, the company is clearly demonstrating that it has outmaneuvered its largest competitor in hospitality software, Oracle (ORCL), who barely addresses the business unit on its earnings calls, the analyst notes. Sutton also likes the company's position against its macro-environment, where five out of the seven key verticals are still in recovery, providing incremental upside potential.
GBA UPGRADE TO BUY- AGYS $39.50
Roth says timing of FDA nicotine decision 'couldn't be better' for 22nd Century 08:34 XXII Roth Capital analyst Brian Wright notes the FDA officially announced it will be pursuing a maximum nicotine content level in all cigarettes sold in the United States. While this is an early step in a multi-year process with the proposed rule not expected until May 2023, the timing of the decision couldn't be better for 22nd Century's launch of its 95% reduced nicotine content cigarettes, the analyst contends. These are the only FDA-approved minimum nicotine content cigarettes on the market, he adds. Wright reiterates a Buy rating on 22nd Century's shares with a price target of $6.
Van draw a nice chart of DOCU that's the one you wanted to buy at $66/ it's $58
after today you will be down $10 a share.
I said Buy DBX because it's safer. In that same time period DBX went from $22 to $21.50/
1 month DBX $22.50- $21.
Docu- $66.44--- $58.44
The idea is to spare the children huge $10 losses if possible. That's why I have created the special radio savant portfolio
RADIO SAVANT PORTFOLIO- GBA Buys- 
1- PLTR- $7.50-------> $8.04--> $8.24
2- Coca Cola- $61.00--> $59
3- Nutrian- $84.25--------> $87---->$83!
4- FORMULA 1-- $55.85 FWONA
5- XXII--- $1.78 <---------- Watch Today!
6- NIO $18.58 ------------> $20.77
7- Boston Scientific $36.10
8- DUKE ENERGY - $101.25 (VAN)
1- PLTR- $7.50-------> $8.04--> $8.24
2- Coca Cola- $61.00--> $59
3- Nutrian- $84.25--------> $87---->$83!
4- FORMULA 1-- $55.85 FWONA
5- XXII--- $1.78 <---------- Watch Today!
6- NIO $18.58 ------------> $20.77
7- Boston Scientific $36.10
8- DUKE ENERGY - $101.25 (VAN)
I can only do short sessions now. I'll check back in at 2:00 pm.
IDEAS))))))))))
A) GEVO $2.60
B) DBX $21
IDEAS))))))))))
A) GEVO $2.60
B) DBX $21
I removed The Duke.RADIO SAVANT PORTFOLIO- GBA Buys-
1- PLTR- $7.50-------> $8.04--> $8.24
2- Coca Cola- $61.00--> $59
3- Nutrian- $84.25--------> $87---->$83!
4- FORMULA 1-- $55.85 FWONA
5- XXII--- $1.78 <---------- Watch Today!
6- NIO $18.58 ------------> $20.77
7- Boston Scientific $36.10
8- DUKE ENERGY - $101.25 (VAN)
Replaced with Nextera.